SCHEMBL19956902

SCHEMBL19956902

CNc1c(NCC(C)C)c(=O)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 2/20 0.36
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CYP2C19 P33261 3/20 0.33
CYP2D6 P10635 2/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33
ESR1 P03372 2/20 0.32
ITGB1 P05556 1/20 0.32
ITGA4 P13612 1/20 0.32
ADH1B P00325 1/20 0.31
ADH1C P00326 1/20 0.31
ADH1A P07327 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16674396 0.91 KDM4E (0.42) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL24586977 0.83 SMN1; SMN2 (0.34) KDM4EALDH1A1MAPT
SCHEMBL16674371 0.82 KDM4E (0.38) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL21472332 0.78 POLB (0.39) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL18194484 0.77 KDM4E (0.35) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL16259076 0.76 GRIN2D (0.48) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL19173939 0.75 GRIN2D (0.35) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL24805675 0.74 HDAC1 (0.35) KDM4EMEN1KMT2AALDH1A1GAA
SCHEMBL409685 0.74
SCHEMBL409684 0.73 ACHE (0.32) KDM4EALDH1A1GAAMAPTACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 KDM4E 843/4885MEN1 1450/4885KMT2A 1030/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 KDM4E 843/4885MEN1 1450/4885KMT2A 1030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.